CD38 and acute myeloid leukemia: It has been reported that affinity optimization of CD38 CAR could reduce “on‐target, off‐tumor” effects when targeting MM.[29] Despite the success of CD38 CAR targeting MM, AML, and B‐ALL, the application of CD38 CAR‐T cells in the treatment of T‐ALL is scarce.